Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Y-mAbs Therapeutics stock

Own Y-mAbs Therapeutics stock in just a few minutes.

Y-mAbs Therapeutics, Inc is a biotechnology business based in the US. Y-mAbs Therapeutics shares (YMAB) are listed on the NASDAQ and all prices are listed in US Dollars. Y-mAbs Therapeutics employs 125 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Y-mAbs Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – YMAB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Y-mAbs Therapeutics share price

Use our graph to track the performance of YMAB stocks over time.

Y-mAbs Therapeutics shares at a glance

Information last updated 2021-04-23.
52-week range$24.78 - $55.22
50-day moving average $31.13
200-day moving average $41.98
Wall St. target price$57.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.83

Buy Y-mAbs Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Y-mAbs Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Y-mAbs Therapeutics financials

Revenue TTM $20.8 million
Gross profit TTM $18.5 million
Return on assets TTM -43.03%
Return on equity TTM -78.32%
Profit margin 0%
Book value $2.60
Market capitalisation $1.2 billion

TTM: trailing 12 months

Shorting Y-mAbs Therapeutics shares

There are currently 3.6 million Y-mAbs Therapeutics shares held short by investors – that's known as Y-mAbs Therapeutics's "short interest". This figure is 27.9% up from 2.8 million last month.

There are a few different ways that this level of interest in shorting Y-mAbs Therapeutics shares can be evaluated.

Y-mAbs Therapeutics's "short interest ratio" (SIR)

Y-mAbs Therapeutics's "short interest ratio" (SIR) is the quantity of Y-mAbs Therapeutics shares currently shorted divided by the average quantity of Y-mAbs Therapeutics shares traded daily (recently around 354765.94700687). Y-mAbs Therapeutics's SIR currently stands at 10.19. In other words for every 100,000 Y-mAbs Therapeutics shares traded daily on the market, roughly 10190 shares are currently held short.

However Y-mAbs Therapeutics's short interest can also be evaluated against the total number of Y-mAbs Therapeutics shares, or, against the total number of tradable Y-mAbs Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Y-mAbs Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Y-mAbs Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.1082% of the tradable shares (for every 100,000 tradable Y-mAbs Therapeutics shares, roughly 108 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Y-mAbs Therapeutics.

Find out more about how you can short Y-mAbs Therapeutics stock.

Y-mAbs Therapeutics share dividends

We're not expecting Y-mAbs Therapeutics to pay a dividend over the next 12 months.

Y-mAbs Therapeutics share price volatility

Over the last 12 months, Y-mAbs Therapeutics's shares have ranged in value from as little as $24.78 up to $55.22. A popular way to gauge a stock's volatility is its "beta".

YMAB.US volatility(beta: 1.24)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Y-mAbs Therapeutics's is 1.2445. This would suggest that Y-mAbs Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Y-mAbs Therapeutics overview

Y-mAbs Therapeutics, Inc. , a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site